DB16358ExperimentalProtein Based Therapies
MW33 is a recombinant fully human antibody to SARS-CoV-2. This antibody injection is currently being investigated against COVID-19 in the clinical trial NCT04533048 (A Clinical Study to Evaluate MW33 Injection).
- Mechanism
- Curator reviewed · 1 reference
The antibody MW33 targets the S protein epitope and is currently being investigated against COVID-19.
- Code names
- MW33
What you can answer from here — as of March 06, 2025
Which companies are running trials of MW33, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account